RxDoctor Payments Data

Scott Southworth, MD

Internal Medicine · Bountiful, UTNPI 1972602910

Payments from drug & device makers

$5,882in general payments, 2019–2025

Across 385 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$688
  • Astellas Pharma US Inc$569
  • Amgen$498
  • Novartis$487
  • Boehringer Ingelheim$407
  • AstraZeneca$365
  • plus $3K from 41 others
$500in research payments, 2019–2025

Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Lucid Diagnostics Inc.$500

What the payments were for

  • Food & beverage$5,81999%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,882 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$120,091
Medicare patients
338
Services billed
1,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$87,855
OzempicSemaglutide68$67,651
XareltoRivaroxaban27$37,133
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$25,909
MyrbetriqMirabegron33$22,957
Levothyroxine Sodium196$8,322
GemtesaVibegron12$7,970
AbrysvoRsv Vacc, Pref A And Pref B/Pf17$5,159
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,682
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,636
Fondaparinux Sodium12$3,629
Omeprazole201$3,266
Atorvastatin Calcium332$3,162
LantusInsulin Glargine,hum.Rec.Anlog17$2,346
Gabapentin134$2,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$688$93,014111 claims
Novo NordiskOzempic$48$67,65168 claims
Johnson & JohnsonXarelto$122$37,13327 claims
Astellas Pharma US IncMyrbetriq$569$22,95733 claims
Sumitomo Pharma America, Inc.Gemtesa$131$7,97012 claims
GSKShingrix$147$3,63617 claims
Sanofi-aventis U.S. LLCLantus$248$2,34617 claims
AbbVieSynthroid, Armour Thyroid$189$2,00359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Bountiful

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →